Demand for weight-loss drugs like GLP-1s has surged in the last year, with user numbers more than doubling since 2024, according to Vox. This rapid expansion, however, is leading to the discovery of new side effects, including a mysterious symptom that is emerging in some users. Simultaneously, the field of cancer research continues to evolve, with a recent correction made to a Nature article regarding EGFR blockade in colorectal cancer.
The popularity of GLP-1s, which were heavily advertised during the Super Bowl, has created a rapidly expanding industry, as reported by Vox. While fatigue and nausea are common side effects, new issues are surfacing as more people use the drugs. Dr. Sera Lavelle, a clinical psychologist, has observed these emerging side effects.
In other news, a correction was issued to a Nature article published on September 30, 2015, concerning the genomic landscape of response to EGFR blockade in colorectal cancer. The correction, available as a supplement, addressed an error in Extended Data Fig. 8, where a micrograph was inadvertently duplicated during figure preparation. The corrected figure now displays the appropriate image showing phospho-ERK levels in a MAP2K1-mutant patient-derived xenograft exposed to a MEK inhibitor.
The news this week, as compiled by multiple sources, also encompasses a variety of other topics. These include advancements in cell therapy for autoimmune disorders, studies on the benefits of kefir and prebiotic fiber, and the EPA's reversal on start-stop technology. Additionally, there are discussions on AI's impact on music and the rise of weight-loss drugs like GLP-1s, according to Vox. Another Vox article highlights government shutdowns, the ongoing war in Ukraine, and concerns about Olympic athlete performance.
VentureBeat's reporting discusses the cyclical nature of technological advancements, illustrating how growth often appears exponential but experiences plateaus and shifts. The article uses the analogy of the Great Pyramid to show how advancements, like those in computing power, transition from one area (CPUs) to another (GPUs and now potentially LLMs) as growth slows in the initial domain.
AI Experts & Community
Be the first to comment